Thursday 25 Jul, 2024 11:28 AM
Site map | Locate Us | Login
   Volumes soar at RBL Bank Ltd counter    Craftsman Automation edges lower after weak Q1 performance    L&T gains as Q1 PAT rises 12% YoY to Rs 2,786 cr    JK Paper drops as Q1 PAT slips 55% YoY to Rs 140 cr    Axis Bank drops as Q1 asset quality deteriorates    FMCG shares gain    Industrials shares rise    Capital Goods stocks edge higher    RVNL gets acceptance letter from South Eastern Railway for Rs 191 crore project    Jindal Steel & Power Ltd Slips 4.53%, BSE Metal index Shed 1.65%    Suzlon Energy Ltd Spikes 4.88%    Dish TV India board OKs raising Rs 1,000 crore    Axis Bank PAT rises 4% YoY to Rs 6,035 crore in Q1 FY25    L&T Q1 PAT rises 12% YoY to Rs 2,786 cr    NSE SME SAR Televenture's FPO ends with 7.46 times subscription 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Biocon's new monoclonal antibodies facility in India get manufacturing approval from EMA
24-Jun-24   09:34 Hrs IST

This approval will provide significant additional capacity to address patients? needs across markets in Europe. The facility has previously been approved to manufacture biosimilar Trastuzumab in September 2022.

The company further informed that the EMA has renewed its good manufacturing practice (GMP) certificates of compliance for its biosimilars manufacturing facility at Bengaluru and its insulin facility in Malaysia following routine GMP inspections. These certificates were issued by the Health Products Regulatory Authority (HPRA), Ireland, on behalf of EMA.

These GMP certifications across our manufacturing sites in India and Malaysia reflect Biocon Biologics? continued compliance with the highest standards of quality and our unwavering commitment to addressing patient needs globally,? Biocon?s spokesperson said in a statement.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune.

It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported 56.74% decline in consolidated net profit to Rs 135.5 crore despite of 3.79% rise in revenue from operations to Rs 3,917.1 crore in Q4 FY24 over Q4 FY23.

The scrip shed 0.67% to currently trade at Rs 343.30 on the BSE.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 34155666
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd